The American Academy of Dermatology (AAD) 2023 Annual Meeting took place last month in New Orleans, Louisiana, and The American Journal of Managed Care® was there to cover the latest news—catch up on what you may have missed.
Here are the top 5 stories from the American Academy of Dermatology (AAD) 2023 Annual Meeting, which took place in New Orleans, Louisiana, from March 17 to 21, 2023.
5. Dermatology Data Can Direct Policy Priorities, but Gaps Reflect Inequities of Care
Speakers at AAD 2023 highlighted the potential of DataDerm to tell the story of dermatological care in the United States, but some also cautioned that the registry only reflects those who have access to care in the first place.
4. Posters Show Success of Ruxolitinib Cream in Alleviating Facial Vitiligo Symptoms, Reducing Noticeability
A pair of posters showed the efficacy of ruxolitinib cream in improving symptoms of vitiligo on the face, both as assessed by investigators and by how noticeable the patients felt their vitiligo was.
3. Dermatologists Looking to the Future Will Need to Be Their Own Advocates, Panel Says
A panel assembled at AAD 2023 encouraged the audience of dermatologists to advocate together for needed changes in payment, access, and practice.
2. Dr Sancy Leachman: Melanoma Metastasizes Quickly, Needs to Be Caught Early
While melanoma is one of the most aggressive cancers, making early detection crucial for outcomes, because it is visible on the surface, there are opportunities to catch it early, said Sancy Leachman, MD, PhD, professor and chair in the Department of Dermatology and director of the Melanoma Research Program at the Knight Cancer Institute at Oregon Health and Science University.
1. Experts Herald “Year of the JAK Inhibitor” in Dermatology
A symposium at AAD 2023 convened speakers who presented current data on the use of Janus kinase (JAK) inhibitors in dermatology, including in atopic dermatitis and vitiligo.
Combining Surgical, Nonsurgical Approaches Holds Promise for Treating Facial Acne Scars
May 4th 2024According to a review, recent progress offers hope in the form of treatments, such as combination therapy that utilizes surgical and nonsurgical methods, for individuals with facial acne scars.
Read More
Patients With Actinic Keratosis Prefer Simulated Daylight PDT Over More Painful Red Light PDT
April 22nd 2024A recent study found that patients with actinic keratosis experienced more pain during red light photodynamic therapy (PDT) than simulated daylight PDT, emphasizing the need to understand patient experiences for better treatment decisions.
Read More
Secukinumab Proves Successful in Treating Severe HS, Safety Persists at Week 52
April 11th 2024In a recent study, secukinumab therapy demonstrated adequate safety and efficacy profiles, offering potential benefits for patients with severe hidradenitis suppurativa (HS) who found adalimumab intolerable.
Read More
Delays in HS Diagnosis, Treatment Shed Light on Provider Education Gaps
April 5th 2024Patients with hidradenitis suppurativa (HS) in Canada often wait long periods of time to receive an HS diagnosis and receive evidence-based therapy, highlighting the need for increased interdisciplinary education on HS management.
Read More
Dupilumab Considered Safe, Effective Treatment for Adolescent, Adult Patients With AD
March 20th 2024These posters both used the GLOBOSTAD study, which demonstrated through patient and physician assessments that dupilumab is a safe and effective treatment for adolescent and adult patients with atopic dermatitis (AD).
Read More